139 related articles for article (PubMed ID: 17601341)
21. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
Gasperini C; Pozzilli C; Bastianello S; Giugni E; Horsfield MA; Koudriavtseva T; Galgani S; Paolillo A; Haggiag S; Millefiorini E; Fieschi C
J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
[TBL] [Abstract][Full Text] [Related]
22. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Minagar A; Ma W; Zhang X; Wang X; Zhang K; Alexander JS; Gonzalez-Toledo E; Albitar M
Neurol Res; 2012 Jul; 34(6):611-8. PubMed ID: 22709658
[TBL] [Abstract][Full Text] [Related]
23. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
[TBL] [Abstract][Full Text] [Related]
24. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
25. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
Polman C; Barkhof F; Kappos L; Pozzilli C; Sandbrink R; Dahlke F; Jakobs P; Lorenz A;
Mult Scler; 2003 Aug; 9(4):342-8. PubMed ID: 12926838
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
27. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
28. Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis.
Szczuciński A; Losy J
Folia Neuropathol; 2004; 42(1):15-8. PubMed ID: 15119740
[TBL] [Abstract][Full Text] [Related]
29. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
[TBL] [Abstract][Full Text] [Related]
31. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[TBL] [Abstract][Full Text] [Related]
32. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
[TBL] [Abstract][Full Text] [Related]
33. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
[TBL] [Abstract][Full Text] [Related]
34. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
35. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
[TBL] [Abstract][Full Text] [Related]
36. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
37. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients.
Weinstock-Guttman B; Hong J; Santos R; Tamaño-Blanco M; Badgett D; Patrick K; Baier M; Feichter J; Gallagher E; Garg N; Ramanathan M
Mult Scler; 2006 Oct; 12(5):541-50. PubMed ID: 17086898
[TBL] [Abstract][Full Text] [Related]
38. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis.
Rizzo R; Bortolotti D; Fredj NB; Rotola A; Cura F; Castellazzi M; Tamborino C; Seraceni S; Baldi E; Melchiorri L; Tola MR; Granieri E; Baricordi OR; Fainardi E
Hum Immunol; 2012 Nov; 73(11):1140-6. PubMed ID: 22922127
[TBL] [Abstract][Full Text] [Related]
39. HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.
Mazdeh M; Taheri M; Sayad A; Bahram S; Omrani MD; Movafagh A; Inoko H; Akbari MT; Noroozi R; Hajilooi M; Solgi G
Pharmacogenomics; 2016 Apr; 17(5):489-98. PubMed ID: 27020477
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
